

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>®</sup>

## EDITORIAL

- Wound Infection Rates Following Clean Operative Procedures: Can We Assume Them to Be Low? 455  
RONALD LEE NICHOLS, MD

## ORIGINAL ARTICLES

- Wound Infection Rates in Clean Surgery: A Potentially Misleading Risk Classification 457  
EDMUNDO MACHADO FERRAZ, MD, PHD, FACS; TERCIO SOUTO BACELAR, MD; JOSE LAMARTINE DE ANDRADE AGUIAR, MD; ALVARO ANTONIO BANDEIRA FERRAZ, MD; GILBERTO PAGNOSSIN, MD; JOSE EDMILSON MAZZA BATISTA, MSc
- Rapid Inactivation of Infectious Pathogens by Chlorhexidine-Coated Gloves 463  
SHANTA MODAK, PHD; LESTER SAMPATH, BA; HARVEY S.S. MILLER, BA; IRVING MILLMAN, PHD
- Investigation of an Outbreak of Methicillin-Resistant *Staphylococcus aureus* in Patients With Skin Disease Using DNA Restriction Patterns 472  
RICHARD A. VENEZIA, PHD; VALERIE HARRIS, RN; CYNTHIA MILLER, MD, HILARY PECK, BS; MARIA SAN ANTONIO, RN
- "Through a Drinking Glass and What Was Found There": Pseudocontamination of a Hospital's Drinking Water 477  
STEPHEN A. KLOTZ, MD; RICHARD E. NORMAND, RN; ROBERT. G. KALINSKY, PHD

## SHEA POSITION PAPER

- 'Look-Back' Notifications for HIV/HBV-Positive Healthcare Workers 482  
AIDS COMMITTEE OF THE SOCIETY FOR HOSPITAL EPIDEMIOLOGY OF AMERICA

## TOPICS IN CLINICAL MICROBIOLOGY

- Flavimonas oryzae* (CDC Group Ve-2) 485  
HUMAYUN J. CHAUDHRY, MS, DO; PAUL E. SCHOCH, PHD; BURKE A. CUNHA, MD

## READERS' FORUM

- Predisposing Factors and Antibiotic Use in Nosocomial Infections Caused by *Xanthomonas maltophilia* 489  
DARRELL T. HULISZ, PHARM D; THOMAS M. FILE, MD, FACP

## LETTERS TO THE EDITOR

- A Small Outbreak of Spontaneous Abortion in Four Patients From Two Households 451  
ABDULSAMAD A. ABOOD, MD
- Parenteral Versus Oral Antimicrobials (and Reply) 451  
ANDREAS F. WIDMER, MD  
N. JOEL EHRENKRANZ, MD
- Streptococcus salivarius* Meningitis Following Myelography 454  
CHATRCHAI WATANAKUNAKORN, MD, FACP, FCCP; CHARLOTTE STAHL, RN, MSN, CIC

## SHEA NEWS

491

# Introducing ARROWg<sup>ard</sup> The first and only catheters with built-

Complications due to catheter-related bacteremia are medically unacceptable when the causes are preventable. And in today's health-care climate, the monetary cost of treating nosocomial infection versus the cost of prevention is similarly unacceptable.

Fortunately, the forces of prevention have gained a new weapon.

ARROWg<sup>ard</sup>™ is a patented colo-

nization-resistant chlorhexidine and silver sulfadiazine antiseptic surface molecularly bonded into the polyurethane catheter material along the entire indwelling length of each ARROWg<sup>ard</sup>™ blue line CVC.

A recent study indicates that catheters with ARROWg<sup>ard</sup>™ protection were twofold less likely to be colonized than control catheters and fourfold less likely to produce bacteremia. The study also noted a considerable lengthening of the safe indwelling period for ARROWg<sup>ard</sup>™ catheters compared to control catheters.<sup>1</sup>

ARROWg<sup>ard</sup>™ infection protection is presently available in select multi-lumen™ and single-lumen CVC kits. It will soon be available on other Arrow critical-care products.

**The benefits of CVCs are not without risk**

There is no question that central venous catheterization (CVC) represents

a significant medical advancement, particularly in treatment of the critically ill. However, with increased usage there is an increased risk of CVC-related infection.

The reported frequency of intravascular device-associated bacteremia is between 0.2% and 0.5% for IV peripheral catheters, up to 7.0% for central parenteral nutrition catheters—and from 3.8% to 12.0% for central venous catheters.<sup>2</sup> In short, 80% to 90% of each year's cases of intravascular-related bloodstream infection arise from the use of CVCs.<sup>3</sup> Moreover, a 10% to 20% case fatality rate has been associated with catheter-related bacteremia.<sup>3</sup>

In an address to

the Third International Conference on Nosocomial Infections, Dr. Dennis Maki stated that one-third of nosocomial infections are preventable, especially the 50,000 cases a year that develop from CVCs. Some 80% of these catheter-related infections arise from bacteria found on the skin that migrate down the catheter track, Dr. Maki noted.

Awareness is, of course, part of the battle. But more ammunition is needed. And that's why we developed ARROWg<sup>ard</sup>™.

More infection control means more financial control.

In a study published in 1988


reporting 1986 results, Hampton and Sheretz determined that nosocomial infection added a mean of seven days to a normal hospital stay and increased the cost by a mean of more than \$6,000!

<sup>5</sup> An additional downside: Medicare reimburses very little of the cost if a hospital stay is extended to treat bacteremia.

When you add the increases in cost since these studies were made, the economic impact of CVC-related infection is even more severe. And while new drugs to fight septic infections offer hope of better management in some crisis cases, the extreme costs pose a clinical dilemma for caregivers.

But ARROWg<sup>ard</sup>™ can help reverse those spiraling figures.

Let's say that a hospital places 500 multi-lumen CVCs a year. If the infection rate is 4%, 20 infections result. By



<sup>5</sup> 4% Infection Rate and 20 Nosocomial Infections



# ROWgard<sup>+</sup>™ Blue. y central venous i infection protection.

bringing the infection rate down to 2%, 10 cases would be avoided-and, at the figure of \$6,000 per case for added hospitalization, the added cost for infection would be cut in half, from \$120,000 to \$60,000. At a cost of \$68.20 per ARROWgard™ multi-lumen CVC kit, or \$34,100 for 500 multi-lumen CVCs, the hospital retains over half the savings\*



even after subtracting the catheter cost. Even more important than the economics, potentially, lives may be saved.<sup>3</sup> Further, you must consider the unnecessary expenditure of time and energy on the part of your staff and the trauma and suffering of the patient.

## Additional patient and physician benefits.

Select Arrow multi-lumen and single-lumen central venous catheters now carry ARROWgard™ protection. And there are other impressive benefits built into select ARROWgard™ CVC kits and sets. These features add up to better patient care with every use.

- The Arrow Blue FlexTip® is an integral catheter tip which is more pliant than the body. It remains patent yet

deflects in case of inadvertent contact with the vessel walls to reduce perforation risk.

- Flexible thromboresistant polyurethane material softens in situ for excellent indwelling characteristics.

- The Arrow® Raulerson Introducer Syringe\*\*\*

has a hollow plunger barrel containing a patented valving system. It allows a spring-wire guide to be placed directly into the vessel lumen so there's less trauma, less contamination risk, and virtually no chance for air embolism.

- The Arrow Advancer™ saves you time by helping you to easily straighten the "J"-tip spring-wire guide and insert it with one hand, advancing it to the proper position with your thumb.

- A centimeter-marked spring-wire

guide (.025" and .035" diameters available) aids in accurate and positive catheter placement.

MEDIAL 18GA

DISTAL 16G.

PROXIMAL 18

Not only does Arrow offer more benefits, but you have a wider choice of kits, sets, and accessories for central venous catheterization from Arrow than from any other source.

## Ask for our free infection-control information packet

We have prepared a helpful packet on infection control. It contains many of the articles referenced in this brochure and CVC informational literature. For your free packet, call your Arrow representative, or contact us directly by calling 1 800 233-3187, Ext. 3294, and ask for Joanne.

Refer to package insert for current warnings, precautions, and instructions for use.

\* ARROWgard™ is a joint development of Dattex Medical Sciences, Inc., and Arrow International, Inc., using technology developed by Dr. Shanta Modak and colleagues in the Department of Surgery, Columbia University, U.S. Patent Numbers 4,512,237; 4,503,485; 4,581,028; 5,019,096 apply. Other U.S. and foreign patents pending.


\*\* U.S. Patent Number RE-31873; Canadian Patent Number 1,112,533. Foreign patents pending and issued. The Arrow-Howe™ Multi-Lumen Central Venous Catheter is a joint development of Randolph Howe, M.D., Ph.D., and Arrow International, Inc.

\*\*\* U.S. Patent Number 4,851,508. Other U.S. and foreign patents pending. The Arrow Raulerson Syringe is a joint development of J. Daniel Raulerson, M.D. and Arrow International, Inc.

# ARROW®

INTERNATIONAL, INC.

Contact our Customer Relations Department for further information: 3000 Bernville Road, Reading, PA 19605, U.S.A. Distribution worldwide; offices in Canada, Germany, Japan, and France.



\* Contact your Arrow representative for full explanation of this program.



The Society for Hospital Epidemiology of America

---

## Position Search Announcement for

Chief Editor, Infection Control and Hospital Epidemiology  
The Official Journal of the Society for Hospital Epidemiology of America

With the decision of founding Chief Editor, Dr. Richard Wenzel, to move on to other activities, the President and Board of the Society for Hospital Epidemiology of America announce the formation of a Search Committee to review candidates and make a recommendation to the Publications Committee and the Board for a successor. All members of SHEA who might be interested in the editorship are urged to submit the following:

- 1) a copy of your CV and bibliography
- 2) a letter of no more than two pages containing:
  - your proposal on how to further strengthen and improve the journal
  - the potential for local editorial board support and the recruitment of a managing editor to work under your direction
  - your experience to date in journal editing or reviewing journal articles.

An annual budget is provided to help you accomplish your work. Send your letter and CV to:

Chair, Chief Editor Infection Control and  
Hospital Epidemiology Search Committee  
SHEA National Office  
875 Kings Highway  
Suite 200  
West Deptford NJ 08096

---

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>TM</sup>

## CONTENTS

### EDITORIAL

Wound Infection Rates Following Clean Operative Procedures: Can We Assume Them to Be Low? 455

RONALD LEE NICHOLS, MD

### ORIGINAL ARTICLES

Wound Infection Rates in Clean Surgery: A Potentially Misleading Risk Classification 457

EDMUNDO MACHADO FERRAZ, MD, PHD, FACS; TERCIO SOUTO BACELAR, MD;  
JOSE LAMARTINE DE ANDRADE AGUIAR, MD; ALVARO ANTONIO BANDEIRA FERRAZ, MD;  
GILBERTO PAGNOSSIN, MD; JOSE EDMILSON MAZZA BATISTA, MSc

Rapid Inactivation of Infectious Pathogens by Chlorhexidine-Coated Gloves 463

SHANTA MODAK, PhD; LESTER SAMPATH, BA; HARVEY S.S. MILLER, BA,  
IRVING MILLMAN, PhD

Investigation of an Outbreak of Methicillin-Resistant *Staphylococcus aureus* in Patients With  
Skin Disease Using DNA Restriction Patterns 472

RICHARD A. VENEZIA, PhD; VALERIE HARRIS, RN; CYNTHIA MILLER, MD; HILARY PECK, BS;  
MARA SAN ANTONIO, RN

'Through a Drinking Glass and What Was Found There': Pseudocontamination of a Hospital's  
Drinking Water 477

STEPHEN A. KLOTZ, MD; RICHARD E. NORMAND, RN; ROBERT G. KALINSKY, PhD

### SHEA POSITION PAPER

'Look-Back' Notifications for HIV/HBV-Positive Healthcare Workers 482

### AIDS COMMITTEE OF THE SOCIETY FOR HOSPITAL EPIDEMIOLOGY OF AMERICA

### TOPICS IN CLINICAL MICROBIOLOGY

Flavimonas oryzihabitans (CDC Group Ve-2) 485

HUMAYUN J. CHAUDHRY, MS, DO; PAUL E. SCHUCH, PHD; BURKE A. CUNHA, MD

### DEPARTMENTS

Letters to the Editor 451

Readers' Forum 489

SHEA News 491

Meeting Abstracts 494

Medical News 498

Calendar of Events 501

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HOSPITAL EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

**PUBLISHER:** Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (609) 848-1000.

**COPYRIGHT 1992** by The Society for Hospital Epidemiology of America, Inc. and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

**SUBSCRIPTIONS:** Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year—\$80.00; Two years—\$115.00; Three years—\$145.00; Institutional: One year—\$90.00; Two years—\$130.00; Three years—\$170.00. Fellows: \$40 per year. Canada: \$18.00 additional each year plus 7% for Canadian Goods & Services tax; all other countries: \$36.00 additional each year. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$20.00 all other countries.

**REPRINTS:** All requests to reprint or use material published herein should be addressed to Lester J. Robeson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Lester J. Robeson at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

**CHANGE OF ADDRESS:** Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086, and additional entry points. **POSTMASTER:** Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents—Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, and Laboratory Performance Information Exchange System.



## EDITORIAL OFFICES

Vanderbilt University School of Medicine  
A-1131 Medical Center North  
Nashville, TN 37232-2637  
(615) 343-1095; (615) 343-1882 (FAX)  
Email: iche@mcmail.vanderbilt.edu

## EDITOR

Michael D. Decker, MD, MPH

## MANAGING EDITOR

Susan Cantrell

## STATISTICAL EDITOR

Beverly G. Mellen, PhD

## SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

## ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

## SECTION EDITORS

### Beyond Infection Control:

#### The New Hospital Epidemiology

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

### Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

### Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

### From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

### Information Management

John A. Sellick, DO

Buffalo, New York

### The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

### Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

### Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

### Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

### SHEA News

Murray D. Batt, MD

Clarksburg, West Virginia

### Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

### Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

### Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

## EDITORIAL ADVISORY BOARD

Jacques F. Acar, MD	Paris, France
J. Wesley Alexander, MD	Cincinnati, Ohio
Paul Arnow, MD	Chicago, Illinois
Graham A.J. Ayliffe, MD	Birmingham, United Kingdom
Neil L. Barg, MD	Yakima, Washington
Elizabeth Ann Bolyard, RN, MPH, CIC	Atlanta, Georgia
John M. Boyce, MD	Providence, Rhode Island
Professor Dr. Ilja Braveny	Munich, Federal Republic of Germany
Charles Bryan, MD	Columbia, South Carolina
Christian Brun-Buisson, MD	Creteil, France
Donald E. Craven, MD	Boston, Massachusetts
Sue Crow, MSN, RN, CIC	Shreveport, Louisiana
Franz Daschner, MD	Freiburg, Federal Republic of Germany
Leigh G. Donowitz, MD	Charlottesville, Virginia
Charles E. Edmiston, Jr., PhD	Milwaukee, Wisconsin
Theodore C. Eickhoff, MD	Denver, Colorado
Bruce Farber, MD	Manhasset, New York
Victoria J. Fraser, MD	St. Louis, Missouri
Peter C. Fuchs, MD, PhD	Black Butte, Oregon
Richard A. Garibaldi, MD	Farmington, Connecticut
Velvl Greene, PhD, MPH	Beer Sheva, Israel
Robert Gaynes, MD	Atlanta, Georgia
David W. Gregory, MD	Nashville, Tennessee
David K. Henderson, MD	Bethesda, Maryland
Peter N.R. Heseltine, MD	Los Angeles, California
Karen Hoffmann, RN, CIC, MS	Chapel Hill, North Carolina
Marguerite McMillan Jackson, RN, PhD	San Diego, California
Janine Jagger, MPH, PhD	Charlottesville, Virginia
William R. Jarvis, MD	Atlanta, Georgia
Douglas S. Kernodle, MD	Nashville, Tennessee
Robert H. Latham, MD	Nashville, Tennessee
Lewis B. Lefkowitz, MD	Nashville, Tennessee
Hsieh-Shong Leu, MD, MSc	Taipei, Taiwan
Jack Levy, MD	Brussels, Belgium
Victor Lorian, MD	Bronx, New York
Dennis G. Maki, MD	Madison, Wisconsin
Professor Dr. Walter Marget	Munich, Federal Republic of Germany
William J. Martone, MD	Bethesda, Maryland
Allison McGeer, MD	Toronto, Ontario, Canada
John E. McGowan, Jr., MD	Atlanta, Georgia
Jonathan L. Meakins, MD, DSc	Montreal, Quebec, Canada
Raf Mertens, MD	Brussels, Belgium
Robert R. Muder, MD	Pittsburgh, Pennsylvania
Joseph M. Mylotte, MD, CIC	Buffalo, New York
Lindsay Nicolle, MD	Winnipeg, Manitoba, Canada
Juhani Ojajarvi, MD	Helsinki, Finland
Michael T. Osterholm, PhD, MPH	Minneapolis, Minnesota
Jan Evans Patterson, MD	San Antonio, Texas
Sindy M. Paul, MD	Trenton, New Jersey
Michael A. Pfaller, MD	Iowa City, Iowa
Samuel Ponce de Leon, MD, MSc	Mexico City, Mexico
Isaam Raad, MD	Houston, Texas
Manfred L. Rotter, MD, DipBact	Vienna, Austria
Theodore Sacks, MD	Jerusalem, Israel
William E. Scheckler, MD	Madison, Wisconsin
Kent Sepkowitz, MD	New York City, New York
Denis Spelman, MD	Prahran Victoria, Australia
Michael L. Tapper, MD	New York, New York
Clyde Thornsberry, PhD	Brentwood, Tennessee
Professor Leonid P. Titov	Minsk, Republic of Belarus
Timothy R. Townsend, MD	Millwood, Virginia
Antoni Trilla, MD, PhD	Barcelona, Spain
Professor Wang Shu-Qun	Beijing, People's Republic of China
J. John Weems, Jr., MD	Greenville, South Carolina
Robert A. Weinstein, MD	Chicago, Illinois
Professor Dr. W. Weuffen	Greifswald, Federal Republic of Germany
Sergio B. Wey, MD	São Paulo, Brazil
Rebecca Wurtz, MD	Evanston, Illinois

## SLACK Incorporated

6900 Grove Road  
Thorofare, New Jersey 08086  
(609) 848-1000

### Vice President/Group Publisher

Richard N. Roash

### Publisher

John C. Carter

### Editorial Director

Jennifer Kilpatrick

### Production Editor

Shirley P. Strunk, ELS

### Assistant Editor

Eileen C. Anderer

### Circulation Manager

Lester J. Robeson, CCCP

### Production Director

Christine Malin

### Production Coordinator

Joanne Patterson

### Publishing Director/ Advertising

Wayne McCourt

### Pharmaceutical Group Sales Director

Michael LoPresti


### Advertising Sales Representative

Jennine Kane


### Classified/Recruitment Sales Manager

Michele Burch


# WE'VE MAGNIFIED THE PROBLEMS OF NEEDLESTICK INJURIES TO MAKE A POINT.



AIDS VIRUS



HEPATITIS B VIRUS




THE PROTECTIV™  
I.V. CATHETER SAFETY SYSTEM  
Call and request a free copy of the informational  
brochure "The Implications Of Needlesticks".  
\*Dollar figures taken from different studies.  
References available upon request.

It's not a pretty picture. The risks of your healthcare workers contracting Hepatitis B or AIDS from a needlestick injury are greater than ever. And so is the cost of treatment.

Consider that in 1981, before AIDS was recognized, the cost of treating a healthcare worker exposed to a blood-borne disease averaged about \$57. Today, the cost is over \$1,500.

And that's just for the medical treatment. There are also indirect costs to consider.

The cost of lost workdays. Of reduced productivity due to psychological stress. Of recruitment. Not to mention the possibility of OSHA fines, effects on insurance, and legal implications.



Fortunately, there is a way to virtually eliminate the risk of accidental needlesticks from I.V. catheters before they occur. With the new PROTECTIV™ I.V. Catheter Safety System.

## YOUR BEST DEFENSE | THE WAR AGAINST NEEDLESTICKS.

The PROTECTIV I.V. Catheter Safety System offers needlestick protection during and after use. The catheter contains a protective guard that glides over the contaminated needle. A reassuring "click" lets the user know when the needle is locked safely inside the guard.

## THE PROTECTIV™ SAFETY SYSTEM. THE POINT OF MAXIMUM PROTECTION.

Protect your employees by turning your hospital into a protective environment. Encourage your Infection Control

Supervisor to call Critikon for a free cost/benefit analysis today. And make the financial risk of needlestick injuries disappear.

**CRITIKON**

a Johnson & Johnson company  
The Worldwide Leader in I.V. Catheters  
800-237-2033 (FL: 800-282-9151)

© Critikon, Inc 1992

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

## The Society for Hospital Epidemiology of America (SHEA) and SLACK Inc. Copyright and Republication Policy

The Society for Hospital Epidemiology of America (SHEA) and SLACK Inc. hold copyright on *Infection Control and Hospital Epidemiology*. We request that all authors of works transfer to SHEA and SLACK Inc. all rights, title, and interest to such works, including copyright. In accord with the Copyright Act of 1976, we must acquire every author's signature to effect the transfer. A written work cannot be considered for publication until the 'Assignment of Copyright' form is signed by the author or authors and is on file at the editorial offices. Please submit this signed form with your manuscript. In the event that a manuscript is not accepted for publication, this agreement will be returned to the authors.

Signed 'Assignment of Copyright' forms confirm that a work submitted has not previously been published, is not subject to copyright or other rights except those of the author to be transferred to SHEA and SLACK Inc., and is not under consideration for publication elsewhere, except under circumstances communicated to us in writing at the time the work is submitted.

Permission to reproduce any part of the works published by SHEA and SLACK Inc. in *Infection Control and Hospital Epidemiology* in any form or by any means, electronic or mechanical, is not permitted without written permission from SLACK Inc.

### Assignment of Copyright

In consideration of SLACK Incorporated and The Society for Hospital Epidemiology of America (collectively called the 'Publisher') in publishing my (our) submitted manuscript, the undersigned hereby transfer(s), assign(s), and otherwise convey(s) all copyright in the manuscript to the Publisher. The undersigned declares that the manuscript is original and, to the best of the undersigned's knowledge, contains no matter that is libelous or unlawful or that infringed upon anyone else's rights of copyright.

In addition, we affirm that the work is the work of every author listed, and is not under consideration for publication elsewhere, except under circumstances communicated to us in writing at the time the work is submitted.

MANUSCRIPT NUMBER (if known) \_\_\_\_\_ DATE \_\_\_\_\_

AUTHORS \_\_\_\_\_

TITLE \_\_\_\_\_

### ALL AUTHORS

Signature \_\_\_\_\_ Date \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_


Signature \_\_\_\_\_ Date \_\_\_\_\_

This form may be photocopied.



# 74% of plastic thermometer sheaths are perforated after use... significantly increasing the threat of infection.

Minimize this risk with the Tempa•DOT®  
Single-Use Clinical Thermometer System



**Sterile—**  
each Tempa•DOT Thermometer is used only once and discarded, minimizing the risk of passing harmful microorganisms from patient to patient.

**Accurate—**  
innovative thermometric technology provides consistently exact readings. Proven on patients of all ages.

**Fast—**  
Tempa•DOT Thermometers give oral readings in just **60 seconds!**

**Versatile and Economical—**  
suitable for oral, axillary and rectal use throughout the institution, no back-up system necessary. Costs no more than other systems.

1. William Valenti, MD; Kathleen Takacs, RN, MS; Infection Control and Clinical Thermometry: Perforation of Soft Plastic Thermometer Sheaths During Temperature Measurement. *American Journal of Infection Control*, February 1981; Vol. 9, No. 1, pp 1-5

For a free Tempa•DOT Thermometer trial, call 1-800-526-3538  
(In New Jersey, call 908-526-1222)

# Tempa•DOT®

## Single-Use Clinical Thermometers

PyMaH Corporation, 89 Route 206, P.O. Box 1114, Somerville, NJ 08876 USA

# Information for Authors

Manuscripts should consist of new material based on hospital epidemiologic or infection control activities, from the United States or abroad. The Journal welcomes submissions that involve the use of epidemiologic principles and methods to evaluate or improve the delivery of care within healthcare institutions or that address the transmission of infection. Examples of appropriate material include rates, distributions, preventive measures, or cost benefit studies of infections or other adverse events in patients; surveillance; occupational health issues affecting healthcare workers; pertinent regulatory actions; and analyses of resource utilization.

Manuscripts should be accompanied by a cover letter that includes the title of the manuscript and the name, address, telephone, and (if available) fax number of the corresponding author. If blinded review is desired, the cover letter should so request. All manuscripts should be submitted in triplicate (with three copies of figures and tables), typewritten on one side of 8½ × 11-inch paper, double-spaced, and with generous margins. Pages should be numbered consecutively beginning with the title page. The author should keep a complete copy of the manuscript, as submitted manuscripts will not normally be returned (however, original figures, photographs, or other artwork will always be returned).

The organization of the paper should be as follows: title page; abstract; introduction; methods; results; discussion; acknowledgments; references; tables; figures; and figure legends. The main sections and subdivisions should be indicated by side headlines flush with the left margin and two lines above the text. The Arabic numbering system should be used.

## CLINICAL TRIALS

The Editor requests that authors reporting the results of clinical trials describe clearly the following: 1) eligibility criteria; 2) whether or not subjects were admitted before allocation to one of the study groups; 3) the method of randomization; 4) whether the study was "masked," what specific information was masked and whether subjects, clinicians, and evaluators were all masked; 5) the method used to identify treatment complications; 6) an explanation and analysis of subjects lost to follow-up; 7) statistical methods employed; 8) information that led to the determination of the size of the study groups and the expected differences between groups; and 9) indications that studies involving human subjects have been reviewed and approved by their institutional review board.

## RAPID PUBLICATION

A request for rapid publication must be stated in the cover letter, and manuscripts should not exceed ten double-spaced, typewritten pages. The Editor will send the manuscript for rapid review only if the information contained is a unique, scholarly contribution of special importance. Such papers will be published within three to four months of acceptance. No comments will accompany rejected papers, but manuscripts may be resubmitted under the normal publication procedure.

## READERS FORUM

Brief communications are encouraged of approximately four to six typewritten pages containing information that does not represent a formal study. They may summarize unusual experiences or reflect opinions, hypotheses, or impressions related to infection control or hospital epidemiology.

## TITLE PAGE

A separate title page should include the following: title of manuscript; author(s); laboratory or institution of origin with city and state; acknowledgment of grant support; name, address, and telephone number of the corresponding author; and (if different) address to be used for reprint requests. An abbreviated title, to be used as a running head, should be included. This should not exceed four words. A preliminary report or abstract should be credited by use of a footnote to the title. Provide three to six key words (MESH terms are preferred) appropriate for indexing the manuscript. If blinded review was requested, include a second title page that contains only the full and abbreviated titles.

## ABSTRACT

Authors submitting manuscripts reporting the results of clinical investigations should prepare an abstract of no more than 250 words under the following headings: Objective, Design, Setting, Patients (or Participants), Interventions

(if any), Results, and Conclusions. The content following each heading should be as follows:

### 1. Objective

The abstract should begin with a clear statement of the precise objective or question addressed in the report. If more than one objective is addressed, the main objective should be indicated and only key secondary objectives stated. If an *a priori* hypothesis was tested, it should be stated.

### 2. Design

The basic design of the study should be described. The duration of follow-up, if any, should be stated. As many of the following terms as apply should be used.

a. Intervention studies: randomized control trial; nonrandomized control trial; double-blind; placebo control; crossover trial; before/after trial.

b. For studies of screening and diagnostic tests: criterion standard (ie, a widely accepted standard with which a new or alternative test is being compared; this term is preferred to "gold standard"); blinded or masked comparison.

c. For studies of prognosis: inception cohort (subjects assembled at a similar and early time in the course of the disorder and followed thereafter); cohort (subjects followed forward in time, but not necessarily from a common starting point); validation cohort or validation sample if the study involves the modeling of clinical predictions.

d. For studies of causation: randomized control trial; cohort; case-control; survey (preferred to "cross-sectional study").

e. For descriptions of the clinical features of medical disorders: survey; case series.

f. For studies that include a formal economic evaluation: cost-effectiveness analysis; cost-utility analysis; cost-benefit analysis. For new analyses of existing data sets, the data set should be named and the basic study design disclosed.

### 3. Setting

To assist readers in determining the applicability of the report to their own clinical circumstances, the study setting(s) should be described. Of particular importance is whether the setting is the general community, a primary care or referral center, private or institutional practice, ambulatory, or hospitalized care.

### 4. Patients or Other Participants

The clinical disorders, important eligibility criteria, and key sociodemographic features of patients and how they were selected should be provided, including the number of otherwise eligible subjects who were approached but refused. If matching is used for comparison groups, characteristics that are matched should be specified. In follow-up studies, the proportion of participants who completed the study must be indicated. In intervention studies, the number of patients withdrawn for adverse effects should be given.

For selection procedures, these terms should be used, if appropriate: random sample (here "random" refers to a formal, randomized selection in which all eligible subjects have a fixed and usually equal chance of selection); population-based sample; referred sample; consecutive sample; volunteer sample; convenience sample. These terms assist the reader to determine an important element of the generalizability of the study. They also supplement (rather than duplicate) the terms used by professional indexers when articles are entered into computerized databases.

### 5. Intervention(s)


The essential features of any interventions should be described, including their method and duration of administration. The intervention should be named by its most common clinical name (eg, the generic term "chlorthalidone"). Common synonyms should be given as well to facilitate electronic textword searching. This would include the brand name of a drug, if a specific product was studied.

### 6. Results

The main results of the study should be given. Measurements that require explanation for the expected audience of the article should be defined. Important measurements not included in the presentation of results should be declared. As relevant, it should be indicated whether observers were blinded to patient grouping, particularly for subjective measurements. Due to the current limitations of retrieval from electronic databases, results must be given in narrative or point form rather than tabular form. If possible, the results should be accompanied by confidence intervals (eg,

# The Perfect Solution

For Interim Instrument  
Decontamination



Use

**VESTA-SYDE®**

**Protection** when and  
where you need **it most!**

The Vestasyde System: The first and **only** interim instrument decontamination system

- Substantially reduces risk of exposure to blood borne infectious agents, including the HIV-1 (AIDS) virus.
- O.R. compatible

- Hands off handling of soiled instruments
- Easy and convenient to use
- Speeds reprocessing time
- Instrument safe

Use on soiled, contaminated  
*instruments prior to terminal  
cleaning and sterilization*

1-800-325-8005



DIVISION OF CALGON CORPORATION  
SUBSIDIARY OF **MERCK**  
& CO., INC.



95%) and the exact level of statistical significance. For comparative studies, confidence intervals should relate to the differences between groups. For nonsignificant differences for the major study outcome measure(s), the clinically important difference sought should be stated and the confidence interval for the difference between the groups should be given. When risk changes or effect sizes are given, absolute values should be indicated so that the reader can determine the absolute as well as relative impact of the finding. Approaches such as "number needed to treat" to achieve a unit of benefit are encouraged when appropriate; reporting of relative differences alone is usually inappropriate. If appropriate, studies of screening and diagnostic tests should use the terms sensitivity, specificity and likelihood ratio. If predictive values or accuracy are given, prevalence or pretest likelihood should be given as well. No data should be reported in the abstract that do not appear in the rest of the article.

#### 7. Conclusion(s)

Only those conclusions of the study that are directly supported by the evidence reported should be given, along with the clinical application (avoiding speculation and over-generalization); indicate whether additional study is required before the information should be used in normal clinical settings. Equal emphasis must be given to positive and negative findings of equal scientific merit.

To permit quick and selective scanning, the headlines outlined above should be included in the abstract. For brevity, parts of the abstract can be written in phrases rather than complete sentences (eg, 2. *Design. Double-blind randomized trial*, rather than 2. *Design. The study was conducted as a double-blind, randomized trial.*) This technique may make reading less smooth but facilitates selection scanning and allows more information to be conveyed per unit of space.

#### TABLES

Tables should be double-spaced, each on a separate page, and self-contained. Do not use vertical lines or ditto marks. The table number should be typed flush left, with the table title beneath it. Symbols for footnotes are listed below. Abbreviations used in a table should be explained at the bottom of the table after the footnotes.

#### FIGURES

Three sets of unmounted glossy prints should be enclosed in separate envelopes. Indicate lightly on the back margin of each figure the number, name of author, and top.

#### PHOTOGRAPHS

Three copies of each photograph should be submitted. Any identifiable human subject must sign a release form before the photograph can be used. Radiographs and other black-and-white material should be submitted as unmounted glossy prints; 5 × 7-inch size is preferred. A separate identification label should be pasted on each print: do not write directly on the print or use paper clips or staples. Photomicrographs or other color materials should be submitted as color transparencies. Any charges for separation of color photographs, as indicated by the Editor, shall be billed to the author. Actual magnification and staining method should be given where appropriate; electron photomicrographs should have internal scale markers.

#### LEGENDS

Legends should be double-spaced on a separate page.

#### REFERENCES

References should be double-spaced and should be cited consecutively in the text with superscript numbers outside punctuation. A reference to a paper "in press" may be included. Citations such as "in preparation," "submitted for publication," "unpublished data," and "personal communication" should be

given in parentheses in the text only. At the end of each article, references should be listed in the numerical order in which they appear in the text. The names of all authors should be given unless there are more than six, in which case the names of the first three authors are used, followed by "et al." Abbreviations of the names of the journals should conform to *Index Medicus*. Journal titles should be cited as they existed at the time of publication. Unlisted journals should not be abbreviated. Authors are responsible for bibliographic accuracy.

#### 1. Articles

Annunziato D, Goldblum LM. Staphylococcal scalded skin syndrome: a complication of circumcision. *Am J Dis Child*. 1978;132:1187- 1188.

#### 2. Books

Heoprich PD. *Infectious Diseases*. 2nd ed. New York, NY Harper & Row Pubs Inc; 1977:169.

#### 3. Contributions to Books

Schaffner W. Psittacosis: ornithosis, parrot fever. In: Beeson PB, McDermott W, Wyngaarden JB. eds. *Cecil Textbook of Medicine*. 15th ed. Philadelphia, Pa: WB Saunders Co; 1979:336-338.

#### FOOTNOTES

Footnotes to the text and tables should be as few as possible. Each should be typed at the foot of the appropriate page, separated from the text or table by a horizontal line. Designate footnotes by the following symbols in this order: \*, †, ‡, \*\*, ††, ‡‡, etc.

#### ABBREVIATIONS AND NOMENCLATURE

Abbreviations should conform to the Chicago Manual of Style published by The University of Chicago Press, Chicago, Illinois. Abbreviations should be kept to a minimum, preferably confined to the tables. Symbols for units of measurement (mm, ml) should not be followed by periods. Chemical or generic names of drugs are preferred. A proprietary name may be given only after it is preceded by the chemical name the first time it appears. Proprietary names must be followed by the manufacturer, city, and state of location. Unfamiliar terms and abbreviations must be defined when first used.

#### REVIEW PROCESS

Each manuscript will be reviewed by the Editor and at least one other Editorial Board member. Authors will be notified as soon as possible regarding the acceptability of their manuscripts. See "Infection Control and Hospital Epidemiology: The Formal Review Process (1991;12[1]:11-13) for more information regarding the review process.

#### PAGE PROOFS

Page proofs will be sent to the author for approval before being printed.

#### REPRINTS

The senior author will be sent five complimentary copies of the issue in which the article appears. An order form listing reprint prices will be included with complimentary copies of the issue.

#### SUBMISSIONS

##### Mail manuscripts to:

Michael D. Decker, MD, MPH, Editor  
*Infection Control and Hospital Epidemiology*  
 Vanderbilt University School of Medicine  
 A-1131 Medical Center North  
 Nashville, TN 37232-2637  
 (615) 343-1095